

# Sergio Lo Caputo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4659850/publications.pdf>

Version: 2024-02-01

86  
papers

3,096  
citations

172457

29  
h-index

161849

54  
g-index

86  
all docs

86  
docs citations

86  
times ranked

3868  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 472-479.	1.1	2
2	Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees. <i>Frontiers in Immunology</i> , 2022, 13, 820250.	4.8	20
3	Neuropsychiatric Disorders in Pediatric Long COVID-19: A Case Series. <i>Brain Sciences</i> , 2022, 12, 514.	2.3	14
4	Lost to follow-up: a challenge over 10 years. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1621-1626.	1.2	2
5	Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2. <i>Journal of Medical Virology</i> , 2021, 93, 1739-1742.	5.0	32
6	Enhancing care for people living with HIV: current and future monitoring approaches. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 443-456.	4.4	3
7	Injectable Antiretroviral Drugs: Back to the Future. <i>Viruses</i> , 2021, 13, 228.	3.3	7
8	Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss. <i>Scientific Reports</i> , 2021, 11, 9632.	3.3	1
9	Safety and heart rate changes in Covid-19 patients treated with Remdesivir. <i>International Journal of Infectious Diseases</i> , 2021, 112, 254-257.	3.3	18
10	Severity of COVID-19 Patients Predicted by Serum Sphingolipids Signature. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10198.	4.1	45
11	Low Prevalence of Antibodies to SARS-CoV-2 and Undetectable Viral Load in Seropositive Blood Donors from South-Eastern Italy. <i>Acta Haematologica</i> , 2021, 144, 580-584.	1.4	9
12	Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2?. <i>Journal of Clinical Medicine</i> , 2021, 10, 309.	2.4	28
13	Sex and gender differences in COVID-19: an Italian local register-based study. <i>BMJ Open</i> , 2021, 11, e051506.	1.9	29
14	CD46 Genetic Variability and HIV-1 Infection Susceptibility. <i>Cells</i> , 2021, 10, 3094.	4.1	3
15	Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic. <i>Antibiotics</i> , 2021, 10, 1477.	3.7	5
16	Severe systemic thrombosis in a young COVID-19 patient with a rare homozygous prothrombin G20210A mutation. <i>Infezioni in Medicina</i> , 2021, 29, 259-262.	1.1	1
17	Marked decrease in acquired resistance to antiretrovirals in latest years in Italy. <i>Clinical Microbiology and Infection</i> , 2020, 27, 1038.e1-1038.e6.	6.0	0
18	Sterol metabolism modulates susceptibility to HIV-1 Infection. <i>Aids</i> , 2020, 34, 1593-1602.	2.2	12

#	ARTICLE	IF	CITATIONS
19	SARS-COV-2 Serological Profile in Healthcare Professionals of a Southern Italy Hospital. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9324.	2.6	12
20	Baricitinib: A chance to treat COVID-19?. <i>Journal of Medical Virology</i> , 2020, 92, 2343-2344.	5.0	16
21	Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. <i>Digestive and Liver Disease</i> , 2020, 52, 447-451.	0.9	1
22	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1363-1367.	3.0	21
23	A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice. <i>AIDS Reviews</i> , 2019, 20, 75-82.	1.0	2
24	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. <i>HIV Clinical Trials</i> , 2018, 19, 52-60.	2.0	6
25	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). <i>International Journal of Epidemiology</i> , 2017, 46, dyv192.	1.9	15
26	The elderly and direct antiviral agents: Constraint or challenge?. <i>Digestive and Liver Disease</i> , 2017, 49, 1036-1042.	0.9	8
27	Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. <i>AIDS Patient Care and STDs</i> , 2017, 31, 487-494.	2.5	7
28	An intricate case of multidrug resistant <i>Plasmodium falciparum</i> isolate imported from Cambodia. <i>Malaria Journal</i> , 2017, 16, 149.	2.3	7
29	A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection. <i>Microbes and Infection</i> , 2017, 19, 69-74.	1.9	9
30	High Expression of Antiviral and Vitamin D Pathway Genes Are a Natural Characteristic of a Small Cohort of HIV-1-Exposed Seronegative Individuals. <i>Frontiers in Immunology</i> , 2017, 8, 136.	4.8	15
31	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. <i>PLoS ONE</i> , 2017, 12, e0181433.	2.5	9
32	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. <i>PLoS ONE</i> , 2017, 12, e0177402.	2.5	15
33	Identification of a Specific miRNA Profile in HIV-Exposed Seronegative Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 11-19.	2.1	21
34	Short Communication: Immune Activation Is Present in HIV-1-Exposed Seronegative Individuals and Is Independent of Microbial Translocation. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 129-133.	1.1	39
35	Variants in the CYP7B1 gene region do not affect natural resistance to HIV-1 infection. <i>Retrovirology</i> , 2015, 12, 80.	2.0	1
36	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2015, 211, 178-186.	4.0	146

#	ARTICLE	IF	CITATIONS
37	A Regulatory Polymorphism in HAVCR2 Modulates Susceptibility to HIV-1 Infection. PLoS ONE, 2014, 9, e106442.	2.5	13
38	Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Journal of the International AIDS Society, 2014, 17, 19769.	3.0	4
39	Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy. Journal of the International AIDS Society, 2014, 17, 19775.	3.0	0
40	CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy. Journal of the International AIDS Society, 2014, 17, 19509.	3.0	2
41	An Evolutionary Analysis of Antigen Processing and Presentation across Different Timescales Reveals Pervasive Selection. PLoS Genetics, 2014, 10, e1004189.	3.5	42
42	Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 258-267.	2.1	4
43	Evolutionary Analysis Identifies an MX2 Haplotype Associated with Natural Resistance to HIV-1 Infection. Molecular Biology and Evolution, 2014, 31, 2402-2414.	8.9	28
44	Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study. International Journal of Antimicrobial Agents, 2014, 43, 189-194.	2.5	12
45	Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	4.0	7
46	Endoplasmic reticulum aminopeptidase 2 haplotypes play a role in modulating susceptibility to HIV infection. Aids, 2013, 27, 1697-1706.	2.2	28
47	Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing. Journal of Infectious Diseases, 2012, 205, 557-567.	4.0	49
48	Genetic variability at the TREX1 locus is not associated with natural resistance to HIV-1 infection. Aids, 2012, 26, 1443-1445.	2.2	7
49	A Common Polymorphism in <i>TLR3</i> Confers Natural Resistance to HIV-1 Infection. Journal of Immunology, 2012, 188, 818-823.	0.8	104
50	96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience. PLoS ONE, 2012, 7, e39222.	2.5	13
51	Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: a model for HIV immunopathogenesis. Blood, 2011, 118, 5152-5162.	1.4	43
52	Late Presenters in New HIV Diagnoses from An Italian Cohort of HIV-Infected Patients: Prevalence and Clinical Outcome. Antiviral Therapy, 2011, 16, 1103-1112.	1.0	45
53	A POSITIVELY SELECTED APOBEC3H HAPLOTYPE IS ASSOCIATED WITH NATURAL RESISTANCE TO HIV-1 INFECTION. Evolution; International Journal of Organic Evolution, 2011, 65, 3311-3322.	2.3	31
54	Under Representation of the Inhibitory KIR3DL1 Molecule and the KIR3DL1+/BW4+ Complex in HIV Exposed Seronegative Individuals. Journal of Infectious Diseases, 2011, 203, 1235-1239.	4.0	35

#	ARTICLE	IF	CITATIONS
55	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	3.8	42
56	Genetic diversity at endoplasmic reticulum aminopeptidases is maintained by balancing selection and is associated with natural resistance to HIV-1 infection. <i>Human Molecular Genetics</i> , 2010, 19, 4705-4714.	2.9	84
57	TLR Activation Pathways in HIV-1-Exposed Seronegative Individuals. <i>Journal of Immunology</i> , 2010, 184, 2710-2717.	0.8	76
58	Treatment with the Fusion Inhibitor Enfuvirtide Influences the Appearance of Mutations in the Human Immunodeficiency Virus Type 1 Regulatory Protein Rev. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2816-2823.	3.2	18
59	Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects. <i>Antiviral Research</i> , 2009, 83, 118-126.	4.1	6
60	Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy. <i>Infection</i> , 2009, 37, 270-82.	4.7	7
61	The "immunologic advantage"™ of HIV-exposed seronegative individuals. <i>Aids</i> , 2009, 23, 161-175.	2.2	106
62	Clinical Validation and Applicability of Different Tipranavir/Ritonavir Genotypic Scores in HIV-1 Protease Inhibitor-Experienced Patients. <i>Current HIV Research</i> , 2009, 7, 425-433.	0.5	1
63	Difficulties in Classifying A/G Recombinants: Methodological Problems or Genetic Variability?. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 840-846.	1.1	3
64	Apolipoprotein B mRNA "Editing Enzyme, Catalytic Polypeptide" Like 3G: A Possible Role in the Resistance to HIV of HIV-Exposed Seronegative Individuals. <i>Journal of Infectious Diseases</i> , 2007, 195, 960-964.	4.0	87
65	IL-22 Participates in an Innate Anti-HIV-1 Host-Resistance Network through Acute-Phase Protein Induction. <i>Journal of Immunology</i> , 2007, 178, 407-415.	0.8	83
66	The Mucosae-Associated Epithelial Chemokine (MEC/CCL28) Modulates Immunity in HIV Infection. <i>PLoS ONE</i> , 2007, 2, e969.	2.5	26
67	Influence of Genotype 3 Hepatitis C Coinfection on Liver Enzyme Elevation in HIV-1-Positive Patients After Commencement of a New Highly Active Antiretroviral Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 180-185.	2.1	32
68	Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients. <i>Aids</i> , 2005, 19, 653-661.	2.2	34
69	Genotypes at chromosome 22q12-13 are associated with HIV-1-exposed but uninfected status in Italians. <i>Aids</i> , 2005, 19, 1015-1024.	2.2	32
70	HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. <i>Journal of Medical Virology</i> , 2005, 75, 483-490.	5.0	46
71	Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. <i>BMC Infectious Diseases</i> , 2005, 5, 58.	2.9	29
72	A Randomized Controlled Trial to Evaluate Antiretroviral Salvage Therapy Guided by Rules-Based or Phenotype-Driven HIV-1 Genotypic Drug-Resistance Interpretation With or Without Concentration-Controlled Intervention: The Resistance and Dosage Adapted Regimens (RADAR) Study. <i>Clinical Infectious Diseases</i> , 2005, 40, 1828-1836.	5.8	49

#	ARTICLE	IF	CITATIONS
73	HIV-1 Resistance to Dideoxynucleoside Reverse Transcriptase Inhibitors: Genotypic???Phenotypic Correlations. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 36, 1104-1107.	2.1	4
74	Lipid Abnormalities in HIV-Infected Patients Are Not Correlated With Lopinavir Plasma Concentrations. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 35, 324-326.	2.1	21
75	Human $\alpha$ -Defensin in HIV-Exposed But Uninfected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 35, 455-463.	2.1	73
76	Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. <i>Journal of Medical Virology</i> , 2004, 74, 29-33.	5.0	6
77	Comparison between Rules-Based Human Immunodeficiency Virus Type 1 Genotype Interpretations and Real or Virtual Phenotype: Concordance Analysis and Correlation with Clinical Outcome in Heavily Treated Patients. <i>Journal of Infectious Diseases</i> , 2003, 188, 194-201.	4.0	53
78	Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. <i>Aids</i> , 2003, 17, 531-539.	2.2	80
79	HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 776-781.	3.0	4
80	Real Versus Virtual Phenotype to Guide Treatment in Heavily Pretreated Patients: 48-Week Follow-Up of the Genotipo-Fenotipo di Resistenza (GenPheRex) Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 32, 268-280.	2.1	60
81	Modulation of Human Immunodeficiency Virus (HIV)-Specific Immune Response by Using Efavirenz, Nelfinavir, and Stavudine in a Rescue Therapy Regimen for HIV-Infected, Drug-Experienced Patients. <i>Vaccine Journal</i> , 2002, 9, 1114-1118.	3.1	9
82	Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 445-449.	2.1	405
83	Human Immunodeficiency Virus (HIV)-Specific IgA and HIV Neutralizing Activity in the Serum of Exposed Seronegative Partners of HIV-Seropositive Persons. <i>Journal of Infectious Diseases</i> , 1999, 180, 871-875.	4.0	135
84	A role for mucosal immunity in resistance to HIV infection. <i>Immunology Letters</i> , 1999, 66, 21-25.	2.5	16
85	High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. <i>Aids</i> , 1999, 13, 870.	2.2	22
86	HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. <i>Nature Medicine</i> , 1997, 3, 1250-1257.	30.7	399